Company Description
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories.
In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders.
Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
| Country | United States |
| Founded | 1888 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 114,000 |
| CEO | Robert Ford |
Contact Details
Address: 100 Abbott Park Road, Abbott Park North Chicago, Illinois 60064-6400 United States | |
| Phone | 224 667 6100 |
| Website | abbott.com |
Stock Details
| Ticker Symbol | ABT |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000001800 |
| CUSIP Number | 002824100 |
| ISIN Number | US0028241000 |
| Employer ID | 36-0698440 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert B. Ford | Chairman of the Board, President and Chief Executive Officer |
| Philip P. Boudreau | Chief Financial Officer and Executive Vice President of Finance |
| Hubert L. Allen | Executive Vice President, General Counsel and Secretary |
| Daniel Gesua Sive Salvadori | Executive Vice President and Group President of Established Pharmaceuticals and Nutritional Products |
| Lisa D. Earnhardt | Executive Vice President and Group President of Medical Devices |
| Sabina Ewing | Senior Vice President of Business and Technology Services and Chief Information Officer |
| Michael Comilla | Vice President of Investor Relations. |
| Erica L. Battaglia | Vice President and Chief Ethics and Compliance Officer |
| Melissa Brotz | Vice President of Public Affairs and Corporate Marketing |
| Christopher J. Scoggins | Senior Vice President of Commercial Operations, Marketing and Diabetes Care |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 21, 2024 | 144 | Filing |
| Oct 16, 2024 | 8-K | Current Report |
| Sep 12, 2024 | 144 | Filing |
| Sep 4, 2024 | 144 | Filing |
| Jul 31, 2024 | 10-Q | Quarterly Report |
| Jul 18, 2024 | 8-K | Current Report |
| Jun 25, 2024 | 11-K | Annual report of employee stock purchase, savings and similar plans |
| May 30, 2024 | SD | Form - SD |
| May 10, 2024 | 144 | Filing |
| May 7, 2024 | 144 | Filing |